Search results for "Anti-Bacterial Agents"

showing 10 items of 661 documents

Anti-adhesion agents against Gram-positive pathogens

2014

The rise of antibiotic-resistance as well as the deficiency of investments by pharmaceutical companies in the development of new antibiotics, have stimulated the investigation of alternative strategies to conventional antibiotics for counteracting the pathogens. A fundamental step of Gram positive pathogenesis is the bacterial adhesion to the host tissue involving a direct and a specific interaction between bacterial surface molecules and host ligands. Targeting the adhesion is a good strategy to design novel anti-infective drugs agents useful to interfere with the pathogenic process and with a virulence mechanism as biofilm formation. This review is focused on anti-virulence compounds whic…

Microbiology (medical)Antivirulencemedicine.drug_classAntibioticsAdhesionBiologyGram-Positive BacteriaAntimicrobialHost tissueSettore BIO/19 - Microbiologia GeneraleMicrobiologyBacterial AdhesionAnti-Bacterial AgentsMicrobiologyBacterial proteinBacterial adhesinSortase ADrug DiscoverymedicineAnti-adhesion agents antivirulence drugs Gram-positive pathogens
researchProduct

Combination of aztreonam, ceftazidime–avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis

2021

Abstract We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the blaVIM-1 gene and belonged to the high-risk clone sequence type ST235. The patient was successfully treated with surgical debridement plus antibiotic therapy with ceftazidime/avibactam, aztreonam, and amikacin. Time-kill curves showed that this triple antibiotic combination at 1 × MIC was strongly synergic after 8 h, achieving 99.9% killing and maintaining this until 48 h.

Microbiology (medical)AvibactamDrug ResistanceCeftazidimeInfectious and parasitic diseasesRC109-216Aztreonammedicine.disease_causeST235CeftazidimeMicrobiologyCeftazidime–avibactamchemistry.chemical_compoundAztreonamAortic valve replacementDrug TherapyDrug Resistance Multiple BacterialmedicineHumansPseudomonas InfectionsPseudomonas aeruginosa; ST235; VIM-1; aztreonam; ceftazidime-avibactam; osteomyelitisAmikacinAgedPseudomonas aeruginosabusiness.industryceftazidime-avibactamOsteomyelitisBacterialOsteomyelitisGeneral MedicineCeftazidime/avibactammedicine.diseaseAnti-Bacterial AgentsDrug CombinationsInfectious DiseaseschemistryDebridementAmikacinPseudomonas aeruginosaCombinationVIM-1Drug Therapy CombinationFemalebusinessAzabicyclo CompoundsMultiplemedicine.drug
researchProduct

Selective growth-inhibitory effect of 8-hydroxyquinoline towards Clostridium difficile and Bifidobacterium longum subsp. longum in co-culture analyse…

2014

The major risk factor for Clostridium difficile infection (CDI) is the use of antibiotics owing to the disruption of the equilibrium of the host gut microbiota. To preserve the beneficial resident probiotic bacteria during infection treatment, the use of molecules with selective antibacterial activity enhances the efficacy by selectively removing C. difficile. One of them is the plant alkaloid 8-hydroxyquinoline (8HQ), which has been shown to selectively inhibit clostridia without repressing bifidobacteria. Selective antimicrobial activity is generally tested by culture techniques of individual bacterial strains. However, the main limitation of these techniques is the inability to describe …

Microbiology (medical)Bifidobacterium longumbiologymedicine.diagnostic_testClostridioides difficilemedicine.drug_classAntibioticsGeneral MedicineClostridium difficileGut floraFlow CytometryOxyquinolinebiology.organism_classificationAntimicrobialMicrobiologyAnti-Bacterial AgentsFlow cytometryMicrobiologyClostridiamedicineMicrobial InteractionsBifidobacteriumAntibacterial activityIn Situ Hybridization FluorescenceJournal of Medical Microbiology
researchProduct

Sequence type 101 (ST101) as the predominant carbapenem-non-susceptible Klebsiella pneumoniae clone in an acute general hospital in Italy.

2012

Klebsiella pneumoniae is one of the most common multidrug-resistant (MDR) Gram-negative organisms worldwide, responsible for high morbidity and mortality both in hospitals and alternative healthcare settings. Recently, increasing use of carbapenems has promoted the emergence and dissemination of carbapenem-non-susceptible MDR K. pneumoniae strains. All of the CNSKP strains isolated between January 2009 and December 2011 in the General Hospital of Prato (Prato, Italy) were studied. Our findings indicate that, unlike previously reported by other authors from different regions of Italy, K. pneumoniae producing KPC-2 and belonging to ST101 have been established in the area of Prato, Tuscany, It…

Microbiology (medical)CarbapenemSettore MED/07 - Microbiologia E Microbiologia ClinicaKlebsiella pneumoniaeClone (cell biology)Drug resistanceMicrobial Sensitivity TestsSettore MED/42 - Igiene Generale E ApplicataHospitals Generalbeta-LactamsMicrobiologyDrug Resistance BacterialmedicineHumansPharmacology (medical)General hospitalhospitalSequence (medicine)Cross InfectionbiologyGeneral Medicinebiology.organism_classificationST101Anti-Bacterial AgentsKlebsiella InfectionsImipenemKlebsiella pneumoniaeInfectious DiseasesCarbapenemsItalymedicine.drugInternational journal of antimicrobial agents
researchProduct

In vitro anti-Gram-positive and anti-staphylococcal biofilm activity of newly halogenated pyrroles related to Pyrrolomycins

2007

Microbiology (medical)ChemistryStaphylococcusBiofilmGeneral MedicineMicrobial Sensitivity Testshalogenated pyrroleGram-Positive Bacteriaantistaphylococcal biofilm activityIn vitroMicrobiologyAnti-Bacterial AgentsStructure-Activity RelationshipInfectious DiseasesVancomycinBiofilmsStructure–activity relationshipPharmacology (medical)PyrrolespyrrolomycinsGram
researchProduct

Distribution of emm types among group A streptococcal isolates from Serbia.

2010

AbstractThis is the first study concerning the molecular epidemiology of group A streptococcus in Serbia and includes 145 isolates from patients with various infections during the period 2001–2007. The emm types, superantigen profile and susceptibility pattern were determined. Among 31 emm types identified, the most prevalent were emm6, emm12, emm1, and emm58. All isolates showed uniform antimicrobial susceptibility to all tested antibiotics, with the exception of tetracycline and erythromycin (41% and 0.7% resistant strains, respectively). Significant heterogeneity of emm types was found, with a high frequency of emm6 and emm58, as well as a considerable prevalence of tetracycline resistan…

Microbiology (medical)DNA BacterialMaleGenotypemedicine.drug_classTetracyclineStreptococcus pyogenesErythromycinDrug resistanceMicrobial Sensitivity TestsBiologymedicine.disease_causeMicrobiologyMacrolide Antibioticsresistance03 medical and health sciences0302 clinical medicinestomatognathic systemStreptococcal InfectionsGenotypeotorhinolaryngologic diseasesmedicineHumans030212 general & internal medicine0303 health sciencesAntigens BacterialMolecular EpidemiologyPolymorphism GeneticSuperantigensMolecular epidemiology030306 microbiologyStreptococcusGeneral Medicinebacterial infections and mycosesDNA Fingerprinting3. Good healthAnti-Bacterial Agentsstomatognathic diseasesInfectious Diseasesemm typeStreptococcus pyogenesFemaleCarrier ProteinsSerbiamedicine.drugBacterial Outer Membrane ProteinsClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
researchProduct

Bactericidal activity of human milk: stability during storage

2016

Human milk provides infants with defensive factors against many illnesses. This study aims to analyse global bactericidal activity in fresh human milk and evaluate its stability in relation to milk manipulation and its possible alteration following refrigeration. Nineteen milk samples (mature milk) from 19 healthy women are analysed. Viability testing involving a strain of Escherichia coli NCTC 9111, serovar O111:K58(B4):H- was used to determine the bactericidal effect of human milk. Degree of bacteriolysis is calculated as the difference between E. coli counts in controls and in milk samples, expressed as a percentage of the control sample counts. An evaluation of the effect of refrigerati…

Microbiology (medical)Food HandlingClinical BiochemistryImmunologyBiologymedicine.disease_causeMicrobiologyfluids and secretionsRefrigerationFreezingmedicineEscherichia coliHumansImmunology and AllergyFood scienceControl sampleEscherichia coliMature milkMilk HumanPostpartum PeriodBiochemistry (medical)food and beveragesBactericidal effectAnti-Bacterial AgentsInfectious DiseasesFemalePostpartum periodBritish Journal of Biomedical Science
researchProduct

Antimicrobial consumption and antimicrobial resistance: A snapshot of an Italian neuromuscular rehabilitation center

2017

The paper presents a snapshot of the incidence of antimicrobial-resistant microorganisms and antimicrobial consumption in an Italian rehabilitation center over a two-year period (2014-2015). Data on microorganism identification and antimicrobial susceptibility testing were obtained from the diagnostic laboratory of the hospital. A set of indicators was assessed, including the incidence density of resistant isolates per 1000 patient-days (IDRI). Data on antimicrobial consumption, semi-annually, obtained from the hospital pharmacy, were expressed as Defined Daily Dose (DDD) per 1000 patient-days. The most frequently isolated microorganism was Klebsiella pneumoniae (19.3%), and a significant i…

Microbiology (medical)GastrointestinalCathetersBacteriaSettore MED/17 - Malattie InfettiveAntimicrobial consumption; Antimicrobial resistance; DDD per 1000 patient-days; Healthcare-associated infections; Rehabilitation hospital; Anti-Bacterial Agents; Bacteria; Catheters; Drug Utilization; Intubation Gastrointestinal; Italy; Neuromuscular Diseases; Risk Factors; Drug Resistance Bacterial; Rehabilitation CentersHealthcare-Associated infections.Drug ResistanceBacterialNeuromuscular DiseasesHealthcare-associated infectionsAntimicrobial resistanceRehabilitation hospitalDDD per 1000 patient-daysRehabilitation CentersDrug UtilizationAnti-Bacterial AgentsItalyRisk FactorsAntimicrobial consumptionDrug Resistance BacterialIntubationIntubation GastrointestinalAntimicrobial consumption; Antimicrobial resistance; DDD per 1000 patient-days; Healthcare-Associated infections.; Rehabilitation hospital; Microbiology (medical)DDD per 1000 patient-day
researchProduct

3,4,5,3’,5’-pentabromo-2-(2’-hydroxybenzoyl) pyrrole: a potential lead compound as anti Gram-positive and anti biofilm agent

2005

The activity against Gram-positive bacteria of 3,4,5,3 ,5 -pentabromo-2-(2 -hydroxybenzoyl)pyrrole I, a synthetic anti-bacterial compound related to pyrrolomycins, was tested in vitro using seven reference bacterial strains and Staphylococcus epidermidis and Staphylococcus aureus preformed biofilms. Compound I was active against all strains tested, with minimum inhibitory concentration (MIC) values ranging from 0.002 to 0.097 mg/l and minimum bactericidal concentrations (MBCs) from 0.37 to 12.5 mg/l. Compound I was also active at low concentrations against preformed S. epidermidis and S. aureus biofilms.

Microbiology (medical)Gram-positive bacteriaTetrazolium SaltsMicrobial Sensitivity Testsmedicine.disease_causeGram-Positive BacteriaMicrobiologychemistry.chemical_compoundMinimum inhibitory concentrationStaphylococcus epidermidisDrug Resistance BacterialmedicineHumansPharmacology (medical)PyrrolesPyrrolebiologyAntimicrobici Staphylococci Anti-biofilmBiofilmAntimicrobici Staphylococci Anti-biofilmGeneral Medicinebiology.organism_classificationAnti-Bacterial AgentsHydrocarbons BrominatedThiazolesInfectious DiseaseschemistryStaphylococcus aureusBiofilmsGentian VioletLead compoundBacteria
researchProduct

In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneum…

2008

In this study, we compared the efficacy of ceftazidime (CAZ) intermittent versus continuous infusion with or without tobramycin (TOB) for the treatment of pneumonia caused by Pseudomonas aeruginosa in rabbits. Treatments were humanised and mimicked intermittent CAZ (iCAZ) (2g three times daily), continuous CAZ (cCAZ) (4g once daily (qd)) and TOB (10mg/kg qd). Minimum inhibitory concentrations (MICs) were 1mg/L and 4mg/L for TOB and CAZ, respectively. Bacterial efficacy in lungs was as follows: control, 9+/-0.6 colony-forming units (CFU)/g; TOB monotherapy, 8+/-0.5CFU/g; iCAZ monotherapy, 7.8+/-1.4CFU/g; cCAZ monotherapy, 8+/-0.4CFU/g (P = 0.005); and iCAZ+TOB, 8+/-0.5CFU/g; cCAZ+TOB, 7.2+/-…

Microbiology (medical)Malemedicine.drug_classAntibioticsColony Count MicrobialCeftazidimeMicrobial Sensitivity TestsCeftazidimeMicrobiologyPseudomonas infectionmedicineTobramycinPneumonia BacterialAnimalsHumansPharmacology (medical)Pseudomonas InfectionsInfusions IntravenousLungAntibacterial agentProtein synthesis inhibitorbusiness.industryAminoglycosideGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesPharmacodynamicsTobramycinDrug Therapy CombinationRabbitsbusinessSpleenmedicine.drugInternational journal of antimicrobial agents
researchProduct